# Curreio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curreio

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.curreio.com
- Total disclosed funding: $4.3M
- Latest round: Series A (Mar 22, 2023)
- Investors on record: 7

## About

Based in Tokyo, Japan, Curreio, Inc. specializes in advanced cryo-electron microscopy technologies that significantly enhance drug discovery processes for pharmaceutical and biotechnology companies.Curreio, Inc. was founded in 2019 in Tokyo, Japan, focusing on innovative microscopy solutions for drug development. The company has completed 2 deals, with its most recent funding round being a Series A on March 22, 2023, which raised JPY 573 million from various investors including 3S Capital and ASAHI KASEI PHARMA CORPORATION. The founder's information is not publicly available.Curreio specializes in advanced cryo-electron microscopy technology, primarily aimed at revolutionizing drug discovery processes. Their core offerings include state-of-the-art electron microscopes designed to visualize biological samples at near-atomic resolution, enabling researchers to gain deeper insights into the structural biology of drug targets. These products are tailored to meet the needs of pharmaceutical companies, academic research institutions, and biotechnology firms engaged in drug development. By providing detailed imaging capabilities, Curreio's technology addresses critical challenges in understanding molecular structures, fostering innovation in drug design. The company serves a global client base, with significant market presence in North America, Europe, and Asia, ensuring broad accessibility for its solutions.Curreio's revenue model is structured around direct sales of its cryo-electron microscopy systems to a range of clients within the pharmaceutical and biotechnology sectors. The company engages in B2B transactions, where customers typically purchase their flagship products outright or through negotiated contracts that may include service agreements for maintenance and support. Revenue is generated not only from initial equipment sales but also from ongoing partnerships that may involve training and consultation services. This transactional framework allows Curreio to establish long-term relationships with its clients, enhancing customer loyalty and ensuring continued engagement with its innovative technologies. Specific pricing plans and product details are aligned with the needs of their clients, reflecting the specialized nature of their offerings in the highly competitive field of drug discovery.In March 2023, Curreio raised JPY 573 million in Series A funding to accelerate its drug discovery pipeline and enhance technology development for cryo-electron microscopy applications. The company aims to launch new products designed to improve structural analysis capabilities, but specific release dates have not been disclosed. Curreio is targeting expansion into new markets across Europe and North America by the end of 2024, leveraging the recent funding to support these initiatives.

## Funding rounds

- Series A, Mar 22, 2023, $4.3M — Beyond Next Ventures, 3S Capital, Gemseki Inc., Ono Venture Investment, ASAHI KASEI PHARMA CORPORATION, UT Founder's Association, DOJIN CAPITAL Co., Ltd.

## Investors

- Beyond Next Ventures (https://capitalatlas.ai/funds/beyond-next-ventures) — Series A
- 3S Capital (https://capitalatlas.ai/funds/3s-capital) — Series A
- Gemseki Inc. — Series A
- Ono Venture Investment (https://capitalatlas.ai/funds/ono-venture-investment) — Series A
- ASAHI KASEI PHARMA CORPORATION — Series A
- UT Founder's Association — Series A
- DOJIN CAPITAL Co., Ltd. — Series A